A clinical trial evaluating ASC11
Latest Information Update: 14 Dec 2022
At a glance
- Drugs ASC 11 (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
Most Recent Events
- 14 Dec 2022 New trial record
- 07 Dec 2022 According to Ascletis media release, China National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for ASC11